Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Midazolam infusion Clear all
Terminated Phase 1Phase 2 Interventional Results available

Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder

NCT01371110
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 25, 2026, 4:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Not applicable Interventional

The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy

NCT01027715
View directory record Official record
Conditions
Seizures, Encephalopathy
Interventions
EEG monitoring and treatment of EEG seizures
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Hour to 72 Hours
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2Phase 3 Interventional

Lorazepam Sedation for Critically Ill Children

NCT00109395
View directory record Official record
Conditions
Critical Illness
Interventions
Lorazepam, Midazolam, Lorazepam CI
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
1 Day to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department

NCT03085563
View directory record Official record
Conditions
Conscious Sedation, Simple Lacerations Less Than 4 cm, Lumbar Punctures, Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement
Interventions
Nitrous Oxide, Midazolam
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 25, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

NCT02727998
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 25, 2026, 4:58 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 25, 2026, 4:58 PM EDT
Active, not recruiting Phase 2 Interventional

Ketamine for Multiple Sclerosis Fatigue

NCT05378100
View directory record Official record
Conditions
Multiple Sclerosis Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 25, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions

NCT01845441
View directory record Official record
Conditions
Stroke, Brain Ischemia, Vasospasm, Intracranial, Hemorrhage, Intracranial
Interventions
Dexmedetomidine, Fentanyl, Midazolam
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 25, 2026, 4:58 PM EDT
Recruiting Not applicable Interventional

Analgesia-First Sedation in Trauma Patients

NCT05751863
View directory record Official record
Conditions
Mechanical Ventilation, Respiratory Failure
Interventions
Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects, Protocol Directed Sedation and Daily Sedation Interruption
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 25, 2026, 4:58 PM EDT
Terminated Phase 4 Interventional Results available

Multimodal Analgesia in Cardiac Surgery (Pilot Study)

NCT02734940
View directory record Official record
Conditions
Heart Diseases
Interventions
Lidocaine, Unrestricted Fentanyl, Ketamine, Precedex, Duramorph
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 25, 2026, 4:58 PM EDT
Terminated Phase 4 Interventional Results available

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

NCT01059929
View directory record Official record
Conditions
Mechanical Ventilation, Critical Illness
Interventions
Dexmedetomidine, Propofol, Fentanyl, Midazolam, Physical and Occupational Therapy
Drug · Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Ketamine Infusion for Adolescent Depression and Anxiety

NCT02579928
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT02461927
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Ketamine + Naltrexone, Ketamine + Placebo, Placebo (psychoactive placebo midazolam) + Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Perioperative Ketamine for Pain With Gastric Bypass

NCT03448068
View directory record Official record
Conditions
Laparoscopic Gastric Bypass Surgery, Ketamine
Interventions
Ketamine, Standard therapy
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 69 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 25, 2026, 4:58 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Dexmedetomidine Sedation With Third Molar Surgery

NCT01017237
View directory record Official record
Conditions
Anesthesia
Interventions
Dexmedetomidine, Midazolam, Ketamine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 25, 2026, 4:58 PM EDT
Active, not recruiting Phase 2 Interventional

Ketamine for Methamphetamine Use Disorder

NCT06496750
View directory record Official record
Conditions
Substance Use Disorders, Substance Use, Methamphetamine Abuse
Interventions
Ketamine Hydrochloride, Midazolam Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
San Leandro, California • Albuquerque, New Mexico • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 4:58 PM EDT
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

NCT03600883
View directory record Official record
Conditions
KRAS p.G12C Mutant Advanced Solid Tumors
Interventions
sotorasib, Anti PD-1/L1, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
39
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 25, 2026, 4:58 PM EDT
Active, not recruiting Phase 2 Interventional

Enhancing Week-long Psychological Treatment for PTSD With Ketamine

NCT05737693
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

NCT00749203
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
Interventions
Midazolam, Ketamine
Drug
Lead sponsor
Dennis Charney
Other
Eligibility
21 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 25, 2026, 4:58 PM EDT
Not yet recruiting Phase 4 Interventional

Ketamine for the Treatment of Refractory Status Epilepticus

NCT07177235
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 25, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke

NCT03263117
View directory record Official record
Conditions
Stroke
Interventions
Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 90 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 25, 2026, 4:58 PM EDT